Budesonide Oral — Membership Pricing

Other medications in Anti-inflammatory

• Dexamethasone
• Methylprednisolone
• Prednisolone
• Betamethasone

About Budesonide Oral

Budesonide oral is a vital medication often prescribed to manage inflammatory conditions, primarily affecting the gastrointestinal tract. As a targeted corticosteroid, it helps reduce inflammation with fewer systemic side effects than traditional steroids. Understanding your treatment options and how to save on costs is crucial, and that's where TheDrugClub steps in to help members access more affordable pricing.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Budesonide Oral is approved for (FDA label)

Budesonide delayed-release capsules are corticosteroid indicated for: Treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon, in patients 8 years and older. ( 1.1 ) Maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months in adults. ( 1.2 ) 1.1 Treatment of Mild to Moderate Active Crohn’s Disease Budesonide delayed-release capsules are indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in patients 8 years of age and older. 1.2 Maintenance of Clinical Remission of Mild to Moderate Crohn’s Disease Budesonide delayed-release capsules are indicated for the maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months in adults.

Source: Read the full FDA label on DailyMed. Label effective date: May 21, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Budesonide Oral (FDA label)

Delayed-Release Capsules: 3 mg ( 3 ) Budesonide Delayed-Release Capsules, 3 mg are white to off-white, free flowing pellets, filled in size '1' hard gelatin capsules having opaque light-orange colored cap printed with "720" in black ink and opaque white body.

Source: FDA prescribing information (DailyMed). Set ID: 5e39c491-2793-410e-b77f-8b3cbe9b6231. SPL document ID: 5252be96-0238-7516-e063-6294a90a2329. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Budesonide Oral (FDA label)

Most common adverse reactions (≥ 5%) in adults are: headache, respiratory infection, nausea, back pain, dyspepsia, dizziness, abdominal pain, flatulence, vomiting, fatigue and pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA prescribing information (DailyMed). Set ID: 5e39c491-2793-410e-b77f-8b3cbe9b6231. SPL document ID: 5252be96-0238-7516-e063-6294a90a2329. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Budesonide Oral (FDA label)

Hypersensitivity to budesonide or any of the ingredients in budesonide delayed-release capsules. ( 4 ) Budesonide delayed-release capsules are contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of budesonide delayed-release capsules. Serious hypersensitivity reactions, including anaphylaxis have occurred [see Adverse Reactions ( 6.2 )].

Source: FDA prescribing information (DailyMed). Set ID: 5e39c491-2793-410e-b77f-8b3cbe9b6231. SPL document ID: 5252be96-0238-7516-e063-6294a90a2329. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Budesonide Oral (FDA label)

Hypercorticism and Adrenal Axis Suppression : May occur with treatment; monitor for signs and symptoms; pediatrics and patients with hepatic impairment may be at increased risk. ( 2.4 , 5.1 , 8.4 , 8.6 ) Symptoms of Steroid Withdrawal in Patients Transferred from Other Systemic Corticosteroids : Taper slowly from corticosteroids with high systemic effects; monitor for withdrawal symptoms and unmasking of allergies (rhinitis, eczema). ( 5.2 ) Immunosuppression and Increased Risk of Infection : Increased risk of viral, bacterial, fungal, protozoal and helminthic infections, including potentially fatal varicella and measles infection. Monitor patients for new or worsening infection and consider drug discontinuation. Avoid use in patients with fungal infections, Strongyloides infestation, cerebral malaria and ocular herpes simplex.

Source: FDA prescribing information (DailyMed). Set ID: 5e39c491-2793-410e-b77f-8b3cbe9b6231. SPL document ID: 5252be96-0238-7516-e063-6294a90a2329. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Budesonide Oral (FDA label)

CYP3A4 Inhibitors (e.g., ketoconazole, grapefruit juice) : Can increase systemic budesonide concentrations: avoid use. ( 2.1 , 7.1 ) 7.1 CYP3A4 Inhibitors Budesonide is a substrate for CYP3A4. Avoid use with CYP3A4 inhibitors. Concomitant oral administration of a strong CYP3A4 inhibitor (ketoconazole) caused an eight-fold increase of the systemic exposure to oral budesonide. Inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine) can increase systemic budesonide concentrations [see Clinical Pharmacology ( 12.3 )] . Grapefruit Juice Avoid ingestion of grapefruit juice with budesonide. Intake of grapefruit juice which inhibits CYP3A4 activity with budesonide can increase the systemic exposure for budesonide [see Clinical Pharmacology ( 12.3 )] .

Source: FDA prescribing information (DailyMed). Set ID: 5e39c491-2793-410e-b77f-8b3cbe9b6231. SPL document ID: 5252be96-0238-7516-e063-6294a90a2329. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.